Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
2016 · Breast Cancer · 48 citations
https://doi.org/10.1007/s12282-016-0666-7
Y
Yoshimi Oouchi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
61
Citations
2
h-index
2
i10-index
Yoshimi Oouchi is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 2, co-authored 4 publications.
Papers by this author
worksDocetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
2016 · Breast Cancer · 12 citations
https://doi.org/10.1007/s12282-016-0677-4
[Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
2018 · PubMed · 1 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat